Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
Holding RCUS?
Track your performance easily
RCUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.52 - $20.31
Previous Close$15.44
Volume610.71K
Average Volume (3M)708.93K
Market Cap
$1.41B
Enterprise Value$370.94M
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$47.00M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Feb 19, 2025EPS Estimate
-$1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.15
Shares Outstanding91,511,609
10 Day Avg. Volume877,119
30 Day Avg. Volume708,930
Standard Deviation0.23
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.37
Price to Sales (P/S)5.05
Price to Cash Flow (P/CF)12.80
P/FCF Ratio12.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.41
Enterprise Value/Gross Profit3.17
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$32.25Price Target Upside102.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Arcus Biosciences News
PremiumCompany Announcements
Arcus Biosciences Reports Q3 2024 Results
PremiumCompany Announcements
Arcus Biosciences Reports Promising Trial Results
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentArcus Biosciences announced a clinical collaboration with AZN for the development of its HIF-2α inhibitor in combination with a PD-1 x CTLA-4 bispecific, which could broaden opportunities in advanced cancer treatments.
Financial PositionArcus' cash runway extends into mid-2027, providing a strong financial position for ongoing and future projects.
Therapeutic AdvancementsDom + Zim combination reduced the risk of death in first-line NSCLC by 36% compared to Zim alone, indicating a promising therapeutic advancement.
Bears Say
Clinical TrialsThe failure of Roche's TIGIT phase 3 study in NSCLC is a setback for the potential of TIGIT therapies, impacting Arcus Biosciences' prospects.
Competitive LandscapeMerck's established commercial infrastructure presents meaningful commercial headwinds for Arcus.
Financial PerformanceReturn on Equity is currently at -41.47%, indicating financial challenges in generating profit from shareholders' equity.
---
Ownership Overview
40.74% Insiders
14.83% Mutual Funds
15.53% Other Institutional Investors
13.45% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCUS FAQ
What was Arcus Biosciences Inc’s price range in the past 12 months?
Arcus Biosciences Inc lowest stock price was $13.52 and its highest was $20.31 in the past 12 months.
What is Arcus Biosciences Inc’s market cap?
Currently, no data Available
When is Arcus Biosciences Inc’s upcoming earnings report date?
Arcus Biosciences Inc’s upcoming earnings report date is Feb 19, 2025 which is in 78 days.
How were Arcus Biosciences Inc’s earnings last quarter?
Arcus Biosciences Inc released its earnings results on Nov 06, 2024. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.056 by $0.056.
Is Arcus Biosciences Inc overvalued?
According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued.
Does Arcus Biosciences Inc pay dividends?
Arcus Biosciences Inc does not currently pay dividends.
What is Arcus Biosciences Inc’s EPS estimate?
Arcus Biosciences Inc’s EPS estimate is -$1.25.
How many shares outstanding does Arcus Biosciences Inc have?
Arcus Biosciences Inc has 91,511,610 shares outstanding.
What happened to Arcus Biosciences Inc’s price movement after its last earnings report?
Arcus Biosciences Inc reported an EPS of -$1 in its last earnings report, beating expectations of -$1.056. Following the earnings report the stock price went up 4.641%.
Which hedge fund is a major shareholder of Arcus Biosciences Inc?
Among the largest hedge funds holding Arcus Biosciences Inc’s share is Woodline Partners LP. It holds Arcus Biosciences Inc’s shares valued at 53M.
---
Arcus Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.25 (102.32% Upside)
$32.25 (102.32% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 757.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.60%
12-Months-Change
Fundamentals
Return on Equity
-49.77%
Trailing 12-Months
Asset Growth
5.12%
Trailing 12-Months
Company Description
Arcus Biosciences Inc
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
---
RCUS Company Deck
---
RCUS Earnings Call
Q3 2024
0:00 / 0:00
---
RCUS Stock 12 Month Forecast
Average Price Target
$32.25
▲(102.32% Upside)
Technical Analysis
Best Analysts Covering RCUS
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-9.59%
assigned a buy rating 2 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -9.59% per trade.
---